Tumor-Associated Macrophages: Untapped Molecular Targets for Improving T Cell-Based Immunotherapy

Strategic Insights -

Researchers from Erasmus University Medical Center Cancer Institute have shed light on the role of tumor-associated macrophages (TAMs) in suppressing T cell responses in solid tumors. According to the study, TAMs can be converted from immune-supportive to immune-suppressive cells, facilitating tumor evasion from T cell control. This perspective highlights the potential of targeting molecular interactions between TAMs and T cells to improve T cell-based therapies for solid tumors.

Key Takeaways:

  • T cell responses are generally curtailed by suppressive mechanisms within the tumor microenvironment (TME), limiting the effectiveness of T cell-based therapies.
  • Tumor-associated macrophages (TAMs) can convert from immune-supportive to immune-suppressive cells, facilitating tumor evasion from T cell control.
  • Immune-suppressive TAMs represent a dominant fraction of immune cells within the TME and are associated with poor prognosis and resistance to immunotherapy.
  • Targeting molecular interactions between TAMs and T cells may aid in improving T cell-based therapies for solid tumors.
  • The study suggests that targeting such molecules and pathways may help to re-boost anti-tumor T cell immunity.

Statistics:

  • According to the study, immune suppressive TAMs represent a dominant fraction of immune cells within the TME (Molecular Cancer, 2025;24(1):261).
  • The study suggests that targeting molecular interactions between TAMs and T cells may aid in improving T cell-based therapies for solid tumors.
  • The research concludes that this perspective may aid the improvement of T cell-based therapies for solid tumors (Molecular Cancer, 2025;24(1):261).

Sources:

  • Molecular Cancer. Tumor-associated macrophages: untapped molecular targets to improve T cell-based immunotherapy. Molecular Cancer, 2025; 24(1):261.
  • BioMed Central. Molecular Cancer: www.molecular-cancer.com
  • Erasmus University Medical Center Cancer Institute. Laboratory of Tumor Immunology, Dept. of Medical Oncology, Rotterdam, Netherlands. Rui M. L. Coelho, Reno Debets, and Dora Hammerl.